Abstracts révélé que l'architecture cellulaire n'est pas bien organisée à trois jours alors que celle-ci semble mature à une semaine.
Cyclic nucleotides mediated signaling determines the regulation of many cardiac function. It is generally admitted that the cyclic nucleotides degradation is due to phosphodiesterases. Recently, cAMP and cGMP were also shown to be extruded from the cell by an active efÁ ux transporter, called MRP4. We investigated whether inhibition of MRP4 may independently control cyclic nucleotides levels and modify functions related to cyclic nucleotides signalling pathways in cardiac myocytes.
Methods -We used silencing RNA or adenovirus encoding MRP4 shRNA (Ad-ShMRP4) to inhibit MRP4 expression in rat cardiomyocytes in vitro. We then performed physiological evaluation of cardiac morphology and function in knock-out MRP4 mice. As a model of adrenergically induced cardiac hypertrophy, miniosmotic pumps containing isoproterenol delivering 20 ìg/g/day for 2 weeks were implanted subcutaneously into 3-months old MRP4 KO and wild type mice. As a model of physiological hypertrophy, animals were housed in a cage with free access to a running monitored wheel.
Results -MRP4 is present in human, mouse and rat cardiomyocytes and over-expressed in case of increased cardiac intracellular cAMP. Using a FRET technique MRP4 inhibition was shown to increase intracellular cAMP level. Adult rat cardiomyocytes infected with Ad-shMRP4 demonstrated a signiÀ cant increase in the calcium current density and in cell size compared to cells infected with the negative control Ad-shLuciferase, suggesting an activation of the cAMP/PKA pathway. While unchallenged young (3 months) MRP4 KO mice displayed normal cardiac parameters, MRP4 KO mice progressively developed signiÀ cant cardiac hypertrophy by 9-12 months of age (HW/BW ; 5.15 vs 4.46 in WT mice). Isoproterenoltreated MRP4 KO mice displayed a signiÀ cant increase in cardiac hypertrophy compared to stimulated WT mice (HW/BW: 6±0.38 vs 5.29±0.34 ; p=0.001). In contrast to the regulation of pathological cardiac hypertrophy, MRP4 inhibition did not affect the physiological cardiac growth response associated with physical training (HW/ BW: 4.83±0.01, vs 4.84±0.13, p=NS), indicating the absence of a regulatory role of MRP4 in physiological cardiac hypertrophy.
Conclusion -These results reveal a unique and important function for MRP4 in stress-dependent cardiac growth by controlling cyclic nucleotides signalling pathways in cardiomyocytes.
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THE RHO/RAC EXCHANGE FACTOR VAV2 CONTROLS NITRIC OXIDE-DEPENDENT RESPONSES IN VASCULAR SMOOTH MUSCLE CELLS
V. SAUZEAU 1 , X.-R. BUSTELO 2 1 Inserm U915-Institut du thorax, Nantes, France 2 Centro de Investigacion del Cancer, Salamanca, Spain
The regulation of arterial contractility is essential for blood pressure control. The GTPase RhoA promotes vasoconstriction by modulating the cytoskeleton of vascular smooth muscle cells. Whether other Rho/Rac pathways contribute to blood pressure regulation remains unknown. We have previously demonstrated that vav2 null mice suffered from serious defects in the cardiovascular system of, including tachycardia, systemic arterial hypertension, extensive cardiovascular remodelling, heart À brosis, and loss of kidney homeostasis. By studying this hypertensive knockout mouse lacking the Rho/Rac activator Vav2, we have discovered a new pathway composed of Vav2, the GTPase Rac1, and the serine/threonine kinase Pak that is critical for nitric oxide-triggered blood vessel relaxation and normotensia. This pathway mediates the Pak-dependent inhibition of phosphodiesterase type 5, a process that favors the inactivation of the RhoA pathway and the depolymerization of the F-actin cytoskeleton in vascular smooth muscle cells. The inhibition of phosphodiesterase type 5 requires its physical interaction with autophosphorylated Pak1 but, unexpectedly, occurs without detectable transphosphorylation events between those two proteins. The administration of phosphodiesterase type 5 inhibitors prevents the development of the hypertension and the cardiovascular disease in Vav2-deÀ cient animals, demonstrating the key role of this signaling route in blood pressure regulation. Taken together, these results unveil the cause of the cardiovascular phenotype of Vav2 knockout animals, identify a new Rac1/Pak1 signaling element, and provide a mechanistic framework to better understand blood pressure control in physiological and pathological states. Chronic agonist stimulation of the β2 Adrenergic Receptors (β2ARs) leads to their lysosomal trafÀ cking and degradation. Previous studies demonstrated that agonist-induced β2AR ubiquitination is necessary for lysosomal targeting and degradation of the receptor. We have now found that the de-ubiquitinating enzymes USP33 and USP20 are recruited to the β2AR complexes, by using cellular coimmunoprecipitation assays. This led to our hypothesis that USP33
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THE DEUBIQUITINASES USP33 AND USP20 COLLABORATIVELY REGULATE BETA2 ADRENERGIC RECEPTOR RECYCLING AND RESENSITIZATION
